Dagan R - Search Results

1

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. Platt HL, et al. Among authors: dagan r. Vaccine. 2022 Jan 3;40(1):162-172. doi: 10.1016/j.vaccine.2021.08.049. Epub 2021 Sep 8. Vaccine. 2022. PMID: 34507861 Free article. Clinical Trial.

2

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.

Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D. Dagan R, et al. J Infect Dis. 2002 Apr 1;185(7):927-36. doi: 10.1086/339525. Epub 2002 Mar 4. J Infect Dis. 2002. PMID: 11920317 Clinical Trial.

3

Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy.

Pelton SI, Dagan R, Gaines BM, Klugman KP, Laufer D, O'Brien K, Schmitt HJ. Pelton SI, et al. Among authors: dagan r. Vaccine. 2003 Apr 2;21(15):1562-71. doi: 10.1016/s0264-410x(02)00681-3. Vaccine. 2003. PMID: 12639477

4

The potential indirect effect of conjugate pneumococcal vaccines.

O'Brien KL, Dagan R. O'Brien KL, et al. Among authors: dagan r. Vaccine. 2003 May 16;21(17-18):1815-25. doi: 10.1016/s0264-410x(02)00807-1. Vaccine. 2003. PMID: 12706665 Review.

5

Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.

Dagan R, Givon-Lavi N, Zamir O, Fraser D. Dagan R, et al. Pediatr Infect Dis J. 2003 Jun;22(6):532-40. doi: 10.1097/01.inf.0000069761.11093.c3. Pediatr Infect Dis J. 2003. PMID: 12799510 Clinical Trial.

6

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T. Jódar L, et al. Among authors: dagan r. Vaccine. 2003 Jul 4;21(23):3265-72. doi: 10.1016/s0264-410x(03)00230-5. Vaccine. 2003. PMID: 12804857 Review.

7

Four antibiotic-resistant Streptococcus pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes, including 2 new serotypes, causing acute otitis media in southern Israel.

Porat N, Barkai G, Jacobs MR, Trefler R, Dagan R. Porat N, et al. Among authors: dagan r. J Infect Dis. 2004 Feb 1;189(3):385-92. doi: 10.1086/381183. Epub 2004 Jan 16. J Infect Dis. 2004. PMID: 14745695

8

Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.

Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J. Dagan R, et al. Pediatr Infect Dis J. 2004 Feb;23(2):91-8. doi: 10.1097/01.inf.0000109221.50972.53. Pediatr Infect Dis J. 2004. PMID: 14872172

9

The potential of pneumococcal conjugate vaccines to reduce antibiotic resistance.

Dagan R. Dagan R. Adv Exp Med Biol. 2004;549:211-9. doi: 10.1007/978-1-4419-8993-2_28. Adv Exp Med Biol. 2004. PMID: 15250535 Review. No abstract available.

10

The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media.

Dagan R. Dagan R. Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):488-94. doi: 10.1097/01.moo.0000145958.12395.ec. Curr Opin Otolaryngol Head Neck Surg. 2004. PMID: 15548905 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

749 results

Search Page